Marea Therapeutics reports Phase 2b TYDAL-TIMI 78 data showing up to 72.2% triglyceride reduction with MAR001

Lisata's subsidiary Marea Therapeutics reported Phase 2b TYDAL-TIMI 78 data showing up to 72.2% triglyceride reduction with MAR001, meeting all Part A objectives.

Detected & updated continuously · Source: Nebula